Wall Street Is Missing the Massive Upside in Novo Nordisk’s Oral Bet

Posted on by

(SeaPRwire) –   By: Christian Pierce

Wall Street is panicking over Novo Nordisk. The stock sits at $42.96. That is a steep drop. It fell 37% from May 2025 levels. Investors see a looming revenue crash. They fear a 9% dip in 2026 sales. This looks like permanent damage. But it might just be a temporary scare. The market is pricing in a collapse. It ignores the underlying resilience.

The data tells a different story. The oral Wegovy pill is exploding. It hit 3 million U.S. prescriptions. That took only five months. The pace is accelerating. One million came in the first ten weeks. Another two million followed quickly. This is not just cannibalizing injections. Over 80% of users are new to GLP-1s. The market is actually growing. Eli Lilly launched Foundayo in April. It is already trailing Novo’s pill. CEO Mike Doustdar sees clear acceleration.

The long-term math remains compelling. TD Cowen raised the 2030 market outlook. They now see $150 billion in global sales. Oral drugs are driving this. Novo trades at a low forward P/E. One model puts intrinsic value at $74. That implies 92% upside from here. The 2026 reset is a buying opportunity. The recovery thesis starts in 2027. This sell-off is an overreaction.

Author bio: Christian Pierce, a chief financial columnist and markets commentator.